Investigating how cannabinoid receptors affect fat and sugar regulation using human fat samples
Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion
This study is testing how cannabinoid receptors in fat cells affect sugar and fat levels in people with abdominal obesity and type 2 diabetes, using samples from their fat tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Male |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dijon) |
| Trial ID | NCT04940962 on ClinicalTrials.gov |
What this trial studies
This study examines the role of cannabinoid receptor 1 (CB1) in regulating endocannabinoid and adipokine secretion in individuals with abdominal obesity and type 2 diabetes. By sampling human abdominal adipose tissue, the research aims to understand how the endocannabinoid system influences metabolic processes related to obesity and diabetes. The study focuses on both diabetic and non-diabetic obese subjects, as well as healthy controls, to explore the differences in endocannabinoid levels and their effects on metabolism. Participants will undergo visceral surgery to provide adipose tissue samples for analysis.
Who should consider this trial
Good fit: Ideal candidates include men or post-menopausal women aged 18 to 80 with a BMI over 30, either diabetic or non-diabetic, who are scheduled for visceral surgery.
Not a fit: Patients with a BMI under 30, those with chronic inflammatory diseases, or those currently undergoing cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing type 2 diabetes and obesity.
How similar studies have performed: While the specific approach of using human adipose tissue biopsies to study CB1's role is novel, related studies have indicated the endocannabinoid system's involvement in obesity and diabetes management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Controls: * men or post-menopausal women aged between 18 and 80 * gave oral consent * to undergo visceral surgery Non-diabetic obese subjects: * men or post-menopausal women aged between 18 and 80 * BMI \> 30 * gave oral consent * to undergo visceral surgery Obese diabetic subjects: * men or post-menopausal women aged between 18 and 80 * type 2 diabetic not treated with Insulin or GLP-1 agonist * BMI \> 30 * gave oral consent * to undergo visceral surgery Exclusion Criteria: * Controls: * Person not covered by national health insurance. * BMI \> 30 * diabetes * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * protected adult Non-diabetic obese subjects: * Person not covered by national health insurance * diabetes * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * protected adult Obese diabetic subjects: * Person not covered by national health insurance * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * type 1 diabetes * secondary diabetes * protected adult
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Pablo ORTEGA DEBALLON
- Email: pablo.ortega-deballon@chu-dijon.fr
- Phone: 03.80.29.37.47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.